KIN News and Press, Kindred Biosciences Inc.

(NewsDirect) Kin Mining NL (ASX:KIN) managing director Andrew Munckton tells Proactive significant assay results have been received from the next four lines of extensional aircore drilling between Cardinia Hill and Collymore within the Eastern Corridor at Cardinia Gold Project. He says the st...

(NewsDirect) Kin Mining NL (ASX:KIN) managing director Andrew Munckton tells Proactive all about the gold stock’s March quarter report. The explorer continued to drill and secure assays for the Cardinia Gold Project’s Helens East and Helens-Rangoon faults — pivotal prospe...

(NewsDirect) Kin Mining NL (ASX:KIN) managing director Andrew Munckton brings Proactive up to speed on the latest gold finds at the Helens-Rangoon fault within Cardinia’s Eastern Corridor. Results from a February drill program confirm that higher-grade, lode-style mineralisation extend...

(NewsDirect) Kin Mining NL (ASX:KIN) exploration manager Leah Moore sits down with Proactive's Elisha Newell to discuss the company’s comprehensive 9,000-metre drilling program. A new exploration phase at Cardinia Gold Project in WA will see the explorer on the hunt for more gold, targ...

(NewsDirect) Kin Mining NL (ASX:KIN) MD Andrew Munckton tells Proactive the company has raised $7.13 million through a non-renounceable rights issue that closed on February 10, 2023. Kin offered one share for every three shares at an issue price of $0.055 and received valid applications for a...

Kindred Biosciences Announces Two New Appointments to Board of Directors PR Newswire SAN FRANCISCO , Feb. 9, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announc...

Kindred Biosciences Initiates Pivotal Efficacy Study of Tirnovetmab (Interleukin-31) Monoclonal Antibody for Canine Atopic Dermatitis PR Newswire SAN FRANCISCO , Dec. 22, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical compa...

Kindred Biosciences (KIN) announces positive results in a pilot field effectiveness study for an antibody therapy in canine inflammatory bowel disease.Over a four-week treatment period, the monoclonal antibody against tumour necrosis factor alpha (anti-TNFα antibody), was assessed in a...

Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study for Anti-TNFα Antibody for Canine Inflammatory Bowel Disease PR Newswire SAN FRANCISCO , Dec. 21, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a bioph...

Ariel Investments’ 13F portfolio value increased from $6.57B to $6.89B this quarter. They increased Gilead Sciences while reducing ViacomCBS during the quarter. The top three positions are Baidu, Philip Morris, and Microsoft and they add up to ~15% of the portfolio. F...